Trial Profile
ARBITER 6: ARterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6 - HDL and LDL Treatment Strategies in Atherosclerosis (HALTS).
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 17 May 2010
Price :
$35
*
At a glance
- Drugs Ezetimibe (Primary) ; Niacin (Primary)
- Indications Atherosclerosis; Coronary disorders
- Focus Therapeutic Use
- Acronyms ARBITER-6-HALTS
- 08 Apr 2010 Updated results published in Journal of the American College of Cardiology.
- 15 Nov 2009 Results were presented during a late-breaking clinical trial session at the 82nd Annual Scientific Sessions of the American Heart Association (AHA).
- 23 Jun 2009 Lead trial centre and sponsor (Abbott Laboratories) added as reported by ClinicalTrials.gov.